Literature DB >> 2368696

Racial differences in the incidence of end-stage renal disease in types I and II diabetes mellitus.

G W Stephens1, J A Gillaspy, D Clyne, A Mejia, V E Pollak.   

Abstract

An increased risk of end-stage renal disease (ESRD) among blacks has been previously shown for most causes of chronic renal failure, including diabetes. Most previous studies have not considered the higher prevalence of diabetes in the black population and have not analyzed relative risk by type of diabetes. We found that the incidence of ESRD among blacks with diabetes was 3.6 times the rate in whites with diabetes. The relative risk for blacks increases progressively with age, reaching a maximum of 6.9 in persons over the age of 65. The incidence of ESRD due to diabetes is higher in the population with type I diabetes (492 per 100,000) than in the population with type II diabetes (71 per 100,000). Blacks have a higher incidence of ESRD in both type I diabetes (odds ratio, 2.96; 95% confidence interval, 1.8 to 4.9) and type II diabetes (odds ratio, 4.9; 95% confidence interval, 3.6 to 6.5). The incidence of ESRD in patients with diabetes varies with age, race, and type of diabetes.

Entities:  

Mesh:

Year:  1990        PMID: 2368696     DOI: 10.1016/s0272-6386(12)80527-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

Review 1.  Renal function changes in middle-aged and elderly Caucasian type 2 (non-insulin-dependent) diabetic patients--a review.

Authors:  A Schmitz
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

2.  The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys.

Authors:  L Guo; P W Sanders; A Woods; C Wu
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Racial differences in diabetes-related psychosocial factors and glycemic control in patients with type 2 diabetes.

Authors:  Leslie Rm Hausmann; Dianxu Ren; Mary Ann Sevick
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

4.  Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.

Authors:  L Yessayan; A Shafiq; E Peterson; K Wells; Y Hu; L K Williams; D Lanfear
Journal:  Transplant Proc       Date:  2015-12       Impact factor: 1.066

5.  Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetic patients in Europe.

Authors:  A E Raine
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

6.  Incidence of end stage renal disease among type 1 diabetes: a nationwide cohort study in Taiwan.

Authors:  Wei-Hung Lin; Chung-Yi Li; Wei-Ming Wang; Deng-Chi Yang; Te-Hui Kuo; Ming-Cheng Wang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

7.  Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study.

Authors:  Takeshi Osonoi; Maki Gouda; Mamiko Kubo; Kenji Arakawa; Toshio Hashimoto; Masanori Abe
Journal:  Diabetes Technol Ther       Date:  2018-08-10       Impact factor: 6.118

Review 8.  The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review.

Authors:  Maria Narres; Heiner Claessen; Sigrid Droste; Tatjana Kvitkina; Michael Koch; Oliver Kuss; Andrea Icks
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

9.  Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes.

Authors:  Richard Sheer; Radhika Nair; Margaret K Pasquale; Thomas Evers; Meghan Cockrell; Alain Gay; Rakesh Singh; Niklas Schmedt
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

10.  Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.

Authors:  Takashi Wada; Kazumi Mori-Anai; Yutaka Kawaguchi; Hideyuki Katsumata; Hidetaka Tsuda; Mitsutaka Iida; Kenji Arakawa; Meg J Jardine
Journal:  J Diabetes Investig       Date:  2021-08-03       Impact factor: 4.232

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.